Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$58.6K Sell
2,300
-416,100
-99% -$10.3M ﹤0.01% 694
2025
Q2
$10.1M Buy
418,400
+398,700
+2,024% +$9.3M 0.38% 54
2025
Q1
$499K Sell
19,700
-63,100
-76% -$1.65M 0.02% 644
2024
Q4
$2.2M Sell
82,800
-264,600
-76% -$7.18M 0.08% 316
2024
Q3
$10.1M Buy
347,400
+40,600
+13% +$1.18M 0.34% 70
2024
Q2
$8.58M Buy
306,800
+262,300
+589% +$7.22M 0.31% 75
2024
Q1
$1.23M Buy
+44,500
New +$1.23M 0.04% 519

Other funds holding PFE

Point72 (DIFC)'s PFE Position: Q3 2024 in Review

Point72 (DIFC) sold out of Pfizer (PFE) in Q3 2024, closing a stake of 888,542 shares — an estimated $25.9M sold.

Point72 (DIFC) first reported a position in PFE in Q1 2024 and held it in 2 quarters. The position peaked at $24.9M in Q2 2024. 2,909 funds tracked by Wall St. Rank hold PFE as of Q3 2024.

  • Point72 (DIFC) reported no remaining Pfizer position as of Q3 2024 after selling out during the quarter.
  • Point72 (DIFC) sold 888,542 Pfizer shares in Q3 2024, an estimated $25.9M.
  • Point72 (DIFC) first reported a position in Pfizer in Q1 2024 and held it in 2 quarters.
  • Point72 (DIFC)'s Pfizer position peaked at $24.9M in Q2 2024.
  • 2,909 funds tracked by Wall St. Rank held Pfizer as of Q3 2024.

Based on Point72 (DIFC)'s 13F filing for Q3 2024, filed 14 Nov 2024.